Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
Christopher Patusky, a director at United Therapeutics Corp (NASDAQ:UTHR), a $14.1 billion market cap pharmaceutical company with excellent financial health and a perfect Piotroski Score of 9 according to InvestingPro, recently sold shares worth approximately $1.55 million, according to a recent SEC filing. The transactions, dated March 19, involved the sale of several blocks of common stock at prices ranging from $307.73 to $313.77 per share.
The sales followed the exercise of stock options, where Patusky acquired 5,000 shares at an exercise price of $175.43 each, totaling $877,150. These transactions were conducted under a pre-established Rule 10b5-1 trading plan.
Following these transactions, Patusky’s direct ownership stands at 900 shares, with an additional 1,100 shares held indirectly by a trust. InvestingPro analysis suggests the stock is currently undervalued, with 12 additional exclusive insights available to subscribers.
In other recent news, United Therapeutics Corporation reported its fourth-quarter 2024 earnings, which fell short of expectations. The company posted an earnings per share (EPS) of $6.19, missing the anticipated $6.68, and recorded revenue of $735.9 million, slightly below the forecasted $739.92 million. Despite the miss, United Therapeutics achieved record annual revenue growth for the third consecutive year, with key products like Tyvaso and Orenitram showing strong revenue increases of 19% and 28%, respectively. Additionally, Goldman Sachs adjusted its price target for United Therapeutics to $293 from $302, maintaining a Neutral rating, due to a modest reduction in Tyvaso forecasts and increased research and development spending. Analyst Chris Shibutani noted that Tyvaso missed expectations, with a 4% sequential decline attributed to contracting efforts and potential competition from Yutrepia by LQDA™. United Therapeutics did not provide financial guidance but highlighted ongoing clinical trials, including the anticipated outcomes of TETON-2 and TETON-1 trials, which are critical for future growth. The company is also advancing its pipeline with significant clinical trial progress, expecting to conclude enrollment in the ADVANCE OUTCOME study later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.